Answer
Retinal vasculitis and/or retinal vascular occlusion have been reported with brolucizumab (Beovu) as immune-mediated events associated with intraocular inflammation, potentially occurring after the first injection or at any time during treatment.
Sources for this answer
- Beovu 120 mg/ml solution for injection in pre filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 12Document updated
Sources checked